第一章 总则 第一条 为了规范广州市香雪制药股份有限公司（以下简称"公司"）选聘 （含续聘、改聘，下同）会计师事务所行为，提高财务信息质量，切实维护股东 利益，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》（以下简称"《证券法》"）、《中华人民共和国会计法》（以下简称"会 计法"）《国有企业、上市公司选聘会计师事务所管理办法》（以下简称"《选聘办 法》"）等法律、法规及《广州市香雪制药股份有限公司章程》（以下简称"《公司 章程》"）的规定，结合公司实际情况，特制定本制度。 第二条 本制度所称选聘会计师事务所，是指公司根据相关法律法规的要求， 聘任会计师事务所对财务会计报告发表审计意见、出具审计报告的行为。公司聘 任会计师事务所从事除财务会计报告审计之外的其他法定审计业务的，可以比照 本制度执行。 第三条 公司聘用或解聘会计师事务所，应当由董事会审计委员会（以下简 称"审计委员会"）审议同意后，提交董事会审议，并由股东大会决定。公司不 得在董事会、股东大会审议批准前聘请会计师事务所开展审计业务。 广州市香雪制药股份有限公司 会计师事务所选聘制度 （五）认真执行有关财务审计的法 ...

深 圳 证 券 交 易 所 关于对广州市香雪制药股份有限公司的 年报问询函 创业板年报问询函〔2024〕第 112 号 广州市香雪制药股份有限公司董事会 ： 2024 年 4 月 30 日，你公司披露 2023 年度报告，审计意 见为保留意见，主要因会计师无法对部分固定资产和在建工 程余额的准确性获取充分、适当的审计证据，也无法确定是 否存在与之相关的关联方资金占用情形。同日披露的《关于 前期会计差错更正及追溯调整的公告》显示，公司对 2021 年年初数、2021 年度、2022 年度财务报表及 2023 年 1-3 季 报中涉及生物岛相关的在建工程、固定资产、其他应收款、 其他应付款等报表项目进行了差错更正，追溯调整后，不会 导致公司已披露的 2021 年度、2022 年度财务报表出现盈亏 性质的改变。请你公司补充说明以下事项： 1.2021 年 4 月，控股股东广州市昆仑投资有限公司（以 下简称"昆仑投资"）将广州香岚健康产业有限公司（以下 简称"协和精准"）100%股权转让给公司；在协和精准转让 1 给公司之前，协和精准在建工程部分中有 5.91 亿元、以及 与此款项相关的以及土地价值为依据计提的 1. ...

Financial Performance - The company's consolidated revenue for 2023 was RMB 2,299.29 million, representing a year-on-year increase of 5.13%[4] - The core traditional Chinese medicine segment saw revenue growth exceeding 100%[4] - The net loss attributable to shareholders was RMB -388.96 million, but this showed a year-on-year improvement of 26.62%[4] - Financial expenses amounted to RMB 241.47 million, significantly impacting profitability[4] - The company's operating revenue for 2023 was ¥2,299,287,682.53, representing a 5.13% increase compared to ¥2,187,069,901.40 in 2022[25] - The net profit attributable to shareholders for 2023 was ¥388,963,842.58, a decrease of 26.62% from ¥533,158,456.93 in 2022[25] - The net cash flow from operating activities increased by 15.86% to ¥263,441,902.31 in 2023, compared to ¥227,377,262.86 in 2022[25] - The total assets at the end of 2023 were ¥8,280,629,970.00, a decrease of 4.18% from ¥9,353,000,530.00 at the end of 2022[25] - The net assets attributable to shareholders decreased by 16.56% to ¥1,924,701,820.00 at the end of 2023, down from ¥2,405,133,050.00 at the end of 2022[25] - The company reported a basic and diluted earnings per share of -0.59 in 2023, an improvement of 26.25% from -0.81 in 2022[25] Asset Management - The company recognized asset impairment losses of RMB 163.34 million across various asset categories[4] - The total assets of the company were CNY 828,063.00 million, a decrease of 4.18% from the beginning of the period[59] - The company's accounts receivable at the end of the reporting period amounted to CNY 768.40 million, with a low risk of bad debts due to its cash-on-delivery policy for most distributors[115] - The company has fixed assets valued at CNY 3,369.35 million and construction in progress of CNY 1,214.43 million, which may lead to high depreciation costs and potential underperformance of expected returns[117] Research and Development - The company is conducting clinical trials for new drugs, including TAEST16001 for synovial sarcoma in Phase II and TAEST1901 for primary liver cancer, which will start Phase I trials[50] - The company has established a complete TCR-T technology platform for tumor-specific antigen discovery and TCR screening, enhancing its R&D capabilities[51] - The company is currently conducting research and development on oral paclitaxel in collaboration with ATHENEX, INC., which has not yet received FDA approval[111] - R&D investment amounted to ¥123,323,635.20 in 2023, a decrease of 7.67% from ¥133,932,747.77 in 2022, with the R&D expense as a percentage of revenue dropping to 5.36% from 6.12%[82] - The company plans to increase R&D efforts in TCR-T cell immunotherapy technology and collaborate with renowned research institutions[106] Market Strategy - The company is focusing on optimizing internal management and expanding into markets outside the province to mitigate market environment impacts[4] - The company expanded its marketing efforts, conducting 500 events under the "Spark Plan" and entering 30 provincial markets nationwide[60] - The company aims to develop a comprehensive health industry chain, integrating TCM cultivation, production, and distribution[44] - The company plans to raise up to ¥95,988.40 million through a private placement to fund projects including the Meizhou Wuhua Industrial Park and digital platform upgrades[64] - The company is exploring partnerships with technology firms to enhance its digital health services, aiming for a 15% increase in user engagement[151] Governance and Compliance - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective operation and protection of shareholder interests[125] - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with regulatory requirements[127] - The company has maintained compliance with corporate governance standards and ensured the protection of shareholders' rights[166] - The company has faced multiple warnings from the China Securities Regulatory Commission regarding non-compliance with information disclosure regulations[154] - The company has been under scrutiny for the actions of its chairman and board secretary, receiving warnings in 2019, 2021, and 2022[155] Environmental Responsibility - The company has established environmental protection measures in compliance with multiple national and local regulations[187] - The company has obtained the necessary environmental impact assessment approvals and pollutant discharge permits for its projects[188] - The wastewater treatment processes at the company’s facilities have consistently met discharge standards, with no exceedances reported[189] - In 2023, the company invested approximately 750,000 yuan in wastewater treatment, environmental monitoring, and solid/hazardous waste management[195] - The company paid an environmental protection tax of 14,300 yuan in 2023[195] Operational Challenges - The company has significant short-term and long-term borrowings, which pose financial risks[6] - The company has faced uncertainties regarding its ability to continue as a going concern, as indicated by the negative net profit figures over the past three years[25] - The company acknowledges the risk of intensified market competition in the traditional Chinese medicine sector, which may affect its sales growth and profitability[110] - The company faces significant operational risks due to industry policy changes, which may adversely affect its business if it fails to adapt its strategies accordingly[107] - The company is facing liquidity constraints impacting investment execution, leading to delays in project funding[93] Future Outlook - Future guidance suggests a revenue target of CNY 2.5 billion for the next fiscal year, indicating a growth expectation of approximately 11%[143] - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[149] - The company is committed to digital transformation, aiming to enhance procurement management and optimize the supply chain to improve production efficiency[106] - The company plans to enhance resource integration towards its main business, improve scale efficiency, and accelerate the divestment of non-core assets[106] - The company is exploring potential mergers and acquisitions to enhance its competitive edge in the pharmaceutical sector[144]

Financial Performance - The company's revenue for Q1 2024 was ¥568,856,745.84, a decrease of 3.37% compared to ¥588,724,855.57 in the same period last year[4] - The net profit attributable to shareholders was -¥35,659,979.04, representing a significant decline of 886.00% from a profit of ¥4,536,891.13 in the previous year[4] - The basic earnings per share were -¥0.05, a drop of 600.00% from ¥0.01 in the previous year[4] - Net profit for Q1 2024 was a loss of CNY 28,629,807.17, compared to a profit of CNY 8,281,817.19 in the same period last year[20] - The total comprehensive income for Q1 2024 was a loss of CNY 28,625,879.70, compared to a gain of CNY 3,899,115.34 in the same period last year[22] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 53.05%, amounting to ¥25,813,931.15 compared to ¥54,977,540.05 in the same period last year[4] - The company's cash and cash equivalents decreased to CNY 117,268,682.42 from CNY 149,316,999.85, reflecting a decline of approximately 21.5%[15] - The ending balance of cash and cash equivalents was 103,037,097.49 CNY, down from 135,223,408.72 CNY at the beginning of the period, indicating a decrease in liquidity[23] - The company received 12,800,000.00 CNY in cash from borrowings, a decrease from 42,950,000.00 CNY in the previous period, suggesting tighter credit conditions[23] - Cash outflow for repaying debts was 10,370,000.00 CNY, compared to 28,441,661.27 CNY in the previous period, indicating a reduction in debt repayment obligations[23] - The company distributed dividends and interest payments totaling 38,492,874.71 CNY, down from 44,261,720.18 CNY in the previous period, reflecting a potential strategy to conserve cash[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,240,218,479.11, a slight decrease of 0.49% from ¥8,280,629,979.39 at the end of the previous year[4] - The equity attributable to shareholders decreased by 1.85%, amounting to ¥1,889,045,772.00 compared to ¥1,924,701,823.57 at the end of the previous year[4] - The company's total liabilities decreased slightly to CNY 5,955,206,531.83 from CNY 5,967,412,152.41[21] - The total current liabilities decreased to CNY 5,152,530,199.12 from CNY 5,161,681,554.89, showing a reduction of about 0.2%[17] Operational Challenges - The company is facing liquidity issues, leading to disputes over loan contracts and the freezing of 110,422,897 shares, which represents 16.70% of the total share capital[13] - The company has initiated debt restructuring strategies, including asset sales and bank loan extensions, to optimize its debt structure[14] - The company is actively seeking support from local government and regulatory bodies to facilitate debt restructuring and financial assistance[14] Other Financial Metrics - Total operating revenue for Q1 2024 was CNY 568,856,745.84, a decrease of 3.0% from CNY 588,724,855.57 in the previous year[19] - Total operating costs increased to CNY 591,588,915.65, up 0.1% from CNY 587,997,301.38[19] - Research and development expenses for Q1 2024 were CNY 17,327,643.17, slightly down from CNY 17,941,867.46[19] - The company reported a cash flow impact from exchange rate changes of 46.22 CNY, contrasting with -54,629.23 CNY in the previous period, suggesting a stabilization in foreign exchange effects[23] - The company did not undergo an audit for the first quarter report, which may affect the reliability of the financial data presented[24]

证券代码:300147 证券简称: 香雪制药 公告编号:2024-016 广州市香雪制药股份有限公司 关于举行 2023 年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广州市香雪制药股份有限公司（以下简称"公司"）于 2024 年 4 月 30 日在 巨潮资讯网披露 2023 年年度报告及其摘要。为了让广大投资者更加深入全面地 了解公司 2023 年度的经营情况，公司将于 2024 年 5 月 10 日（星期五）下午 15 ：00-17：00 在深圳证券交易所提供的"互动易"平台以网络远程的方式举办 2023 年度业绩说明会，投资者可登录"互动易"网站（http://irm.cninfo.com.cn） 进入"云访谈"栏目参与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：公司董事长兼总经理王永辉先生、独立 董事吴杰先生、董事会秘书徐力先生、财务总监牛晓燕女士。 为提升交流的针对性，现就公司本次年度业绩说明会提前向投资者公开征集 问题，广泛听取投资者的意见和建议。投资者可提前登录"互动易"网站进入公 司本次年度业绩说明会页面进 ...

证券代码:300147 证券简称: 香雪制药 公告编号:2024—006 广州市香雪制药股份有限公司 关于涉及重大诉讼案进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次被列入强制执行的情况 公司已将云埔厂区、生物岛 1 号地块相关资产向高新投抵押，抵押物价值 足以覆盖案件涉及的金额，且与高新投的诉讼，公司大股东及实际控制人对相 关事项承担了连带责任保证。目前公司暂未收到法律执行相关的文件，公司及 聘请的律师团队在与高新投友好沟通中，公司所在地的相关政府部门也重视并 广州市香雪制药股份有限公司（以下简称"公司"）通过中国执行信息公开 网（http://zxgk.court.gov.cn）公示信息查询得知公司被申请法院强制执行。 具体情况如下： | 被执行人名称 | 广州市香雪制药股份有限公司 | | --- | --- | | 执行法院 | 广州市黄埔区人民法院 | | 立案时间 | 2024 年 4 月 2 日 | | 案号 | （2024）粤 0112 执 3606 号 | | 执行标的 | 291173760 元 | 公司与广州高新区投 ...

证券代码:300147 证券简称: 香雪制药 公告编号:2024—005 广州市香雪制药股份有限公司 关于涉及重大诉讼案进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广州市香雪制药股份有限公司（以下简称"公司"）子公司广东香雪智慧中 医药产业有限公司收到五华县人民法院的《执行通知书》和《执行裁定书》（（20 24）粤 1424 执 375 号），主要信息如下： | 被执行人名称 | 广东香雪智慧中医药产业有限公司 | 广州市香雪制药股份有限公司 | | --- | --- | --- | | 执行法院 | 五华县人民法院 | 五华县人民法院 | | 立案时间 | 2024 年 3 月 25 日 | 2024 年 3 月 25 日 | | 案号 | （2024）粤 1424 执 375 号 | （2024）粤 1424 执 375 号 | | 执行标的 | 248751088 元 | 248751088 元 | 公司及子公司广东香雪智慧中医药产业有限公司与中国农业银行股份有限 公司五华县支行金融借款合同纠纷，其对公司及子公司广东香雪智慧中医药产 业 ...

证券代码：300147 证券简称：香雪制药 公告编号：2024-004 广州市香雪制药股份有限公司 关于持股 5%以上股东所持股份被司法冻结的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别风险提示： 控股股东累计质押股份数量、累计被冻结股份数量（含本次）占其所持公司 股份数量比例均已超过 80%，请投资者注意相关风险。 近日，广州市香雪制药股份有限公司（以下简称"公司"）通过查询中国证 券登记结算有限责任公司深圳分公司系统，获悉控股股东广州市昆仑投资有限公 司（以下简称"昆仑投资"）所持有公司的部分股份被司法冻结，现将具体情况 公告如下： 一、 股份被冻结的情况 | 股东名称 | 是否为 控股股 | 本次冻结股 | 占所持 股份比 | 占总股 | 是否为限 售股及限 | 起始日 | 到期日 | 冻结执行人 | 原因 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 份/股 | | 本比例 | | | | | | | | 东 | | 例 | | 售类型 | | ...

公司的上诉请求不能成立，应予驳回；一审判决认定事实清楚，适用法律 正确，应予维持。依照《中华人民共和国民事诉讼法》第一百七十七条第一款 第（一）项的规定，判决如下： 证券代码:300147 证券简称: 香雪制药 公告编号:2024—003 广州市香雪制药股份有限公司 关于涉及重大诉讼案进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广州市香雪制药股份有限公司（以下简称"公司"）与广州高新区投资集团 有限公司（以下简称"高新投"）因股权转让纠纷的诉讼事项，公司已分别于 20 22 年 8 月 25 日、2023 年 6 月 30 日、2023 年 12 月 25 日在巨潮网披露了《关于 累计新增诉讼事项的公告》（公告编号:2022—072）、《关于涉及重大诉讼案进展 的公告》（公告编号:2023—033）、《关于新增重大诉讼事项的公告》（公告编号: 2023—069）。近日公司收到了广东省广州市中级人民法院出具的《民事判决书》 （2023）粤 01 民终 22802 号之一，情况如下： 一、判决情况 三、其他事项 驳回上诉，维持原判。 二审案件受理费 ...

证券代码：300147 证券简称：香雪制药 公告编号：2024-002 广州市香雪制药股份有限公司 关于 TAEST16001 注射液新增适应症 申报临床试验获得受理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，广州市香雪制药股份有限公司（以下简称"公司"）子公司香雪生命 科学技术（广东）有限公司（以下简称"香雪生命科学"）向国家药品监督管理 局提交了 TAEST16001 注射液新增适应症临床注册申请，并收到了国家药品监督 管理局核准签发的《受理通知书》（受理号：CXSL2400103）。现将相关情况公告如 下： 一、《受理通知书》主要内容 申报人：香雪生命科学技术（广东）有限公司 申请事项：境内生产药品注册临床试验 产品名称：TAEST16001 注射液 2 结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审查，决 定予以受理。受理号：CXSL2400103。 二、TAEST16001 注射液研发情况 （一）公司子公司香雪生命科学，搭建了具有国际领先水平前沿生物技术医 药研发基地和转化平台，主要开展以具有自主知识产权的高亲和性 T ...